Navigation Links
Inhaled Insulin: A New Modality for Management of Diabetes

It is widely known that diabetes, one of the world’s leading debilitating diseases, has reached overwhelming proportions // . It affects an estimated 194 million adults worldwide. Therefore, there is a huge demand for innovative and effective therapeutic options that are beneficial to the patients.

There are two types of diabetes:

Type-1: Also known as Juvenile Diabetes, it accounts for approximately 5% of all the cases. This type is the direct result of the body’s inability to produce sufficient Insulin required for the breakdown of sugar.

Type-2: This results from the body not availing the Insulin that is present and is often associated with ageing, obesity and lack of physical activity.

On Saturday (June 9, 2006) the pharmaceutical company, Pfizer, announced the arrival of its 'Inhaled Insulin' Exubera, which will be available from July all over the United States. It is the first non-injectable Insulin to be marketed and is a revolutionary change in the management of Diabetes. The drug has been approved by the FDA. This announcement was made by Pfizer, along with its partner Nektar Therapeutics, at the annual scientific meeting of the American Diabetics Association.

It is claimed that the drug is far more user- friendly than the injectable version. A price has not yet been assigned to the drug.

Having been approved by the EU, diabetics in Europe also will have access to the drug.

In the US, the drug has been approved to treat both Type 1 and Type 2 Diabetes. Taken at mealtime, the patient inhales the Insulin through the mouth and the drug then is rapidly delivered into the lungs. The lungs are considered a safe place for its absorption due to its large and permeable surface area. From here it pass into the blood stream.

Pfizer recommends that Type 1 patients use Exubera along with the injections, while the Type 2 patients may use it alone or in combination with the in jections or pills.

Exubera is a boon to those patients with Type 2 Diabetes who are reluctant to be initiated on injectable Insulin and thus delay the treatment by up to four years. They strongly believe that the drug will have a huge impact on the treatment and management of the disease.

A cautionary note from the critics say that small injections of Insulin are far more predictable than any prescribed dose of inhaled Insulin and that it cannot be said with any finality that the inhaled Insulin is definitely superior to its injectable counterpart.

Patients need to consult with their physicians about the utilization of this new mode of treatment for management of diabetes.


Related medicine news :

1. Inhaled Steroids Safe & Effective for Children with Asthma
2. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
3. The Effectiveness Of Inhaled Corticosteroids Studied
4. The Effectiveness Of Inhaled Corticosteroids Studied
5. Inhaled nitric oxide therapy does not reduce death risk of infants
6. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
7. HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy
8. Inhaled Insulin To Be Made Available in India
9. Inhaled Insulin Could Rock The Drug Market Soon
10. High Cost Forces NHS To Reject Inhaled Insulin
11. Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients
Post Your Comments:

(Date:12/1/2015)... , ... December 01, 2015 , ... Lutronic, a leading ... Clarity, the latest addition to the devices for sale in the United States. ... Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy ...
(Date:12/1/2015)... ... 01, 2015 , ... PYA’s latest white paper, “ PYA ... main “pain point” for merging or aligning healthcare provider organizations—when mergers and other ... This quick-read guidance suggests that failing to recognize the power of an ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker ... order to date. , The order will be from the China Disabled Persons’ ... Implant System is an effective solution for children and adults suffering from severe ...
(Date:12/1/2015)... Charlotte, NC (PRWEB) , ... December 01, 2015 ... ... NHS Foundation Trust on receiving the 2015 HSJ Acute Sector Innovation Award on ... of improving the patient care experience, and propose exciting enhancements to the medical ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , Dec. 1, 2015  The ... (HCOs) to develop shared care plans that help ... These care plans will be digitally enabled, incorporate ... unique needs and desires. They will also allow ... a patient,s health journey is optimal. That is ...
(Date:12/1/2015)... Germany , December 1, 2015 /PRNewswire/ ... leading global manufacturer of eye and gaze tracking solutions, ... SMI remote eye trackers as a component of its ... concussions, eye sight, and medical and performance issues in ... part of SMI,s mass-market-ready eye tracking platform, which is ...
(Date:12/1/2015)... THE WOODLANDS, Texas , Dec. 1, ... LXRX )  announced today that top-line data ... results of telotristat etiprate in treating carcinoid ... tumors consistent with the clinical benefit observed ... study was designed as a companion to ...
Breaking Medicine Technology: